Jian-Guo Geng

Title: **Jian-Guo Geng: Innovator in Peptide Inhibition of Inflammation**

Introduction

Jian-Guo Geng is an accomplished inventor based in Oklahoma City, OK, who has made significant contributions to the field of biomedical innovation. With a total of two patents to his name, Geng's work focuses on developing peptide inhibitors that target inflammation, specifically mediated by selectins. His research endeavors have practical applications in clinical settings, aiming to modulate coagulation and inflammatory processes.

Latest Patents

Geng's latest patents revolve around peptide inhibitors of inflammation mediated by selectins. The peptides derived from three regions of the lectin domain of GMP-140, also known as P-selectin, and related selectins such as ELAM-1 (E-selectin) and the lymphocyte homing receptor (L-selectin), have been shown to inhibit neutrophil adhesion to GMP-140. Each patent details the synthesis of peptides characterized by core regions comprising portions of the amino acid sequences of GMP-140. The studies demonstrate that even with alterations in the sequences and flanking regions, the biological activity of these peptides remains intact. These innovations are not just academic; they hold potential for diagnostics and therapeutic applications when combined with suitable pharmaceutical carriers.

Career Highlights

Throughout his career, Jian-Guo Geng has worked with prominent organizations, including Centocor, Inc., where he expanded his expertise in biomedical research. His innovative thinking and dedication to scientific exploration have led to remarkable findings that contribute to the understanding and management of inflammatory processes.

Collaborations

Geng has collaborated with esteemed colleagues such as George A. Heavner and Rodger P. McEver. These partnerships have enriched his research and allowed for a broader impact in the field of peptide science and inflammation management.

Conclusion

In summary, Jian-Guo Geng stands out as a significant figure in biomedicine, particularly in the development of peptide inhibitors targeting selectin-mediated inflammation. His patents reflect both innovation and practicality, paving the way for advancements in healthcare. As research further explores the applications of his findings, Geng's work will likely continue to influence the medical field positively.